QR код

Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Повний опис

Збережено в:
Автори: Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Формат: Artigo
Мова:Inglês
Опубліковано: Wiley 2020-07-01
Серія:Endocrinology, Diabetes & Metabolism
Предмети:
albuminuria
CCR2
diabetes
kidney
MCP‐1
propagermanium
Онлайн доступ:https://doi.org/10.1002/edm2.159
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси